Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids

Not Applicable

• Conditions: Uterine Fibroids

• Registration Number: NCT00277680
• Lead Sponsor: Ullevaal University Hospital

Brief Summary

Women with symptomatic uterine fibroids are treated either by Uterine Fibroid Embolization (UFE) or laparoscopic occlusion. The study hypothesis is that laparoscopic occlusion of uterine vessels and UFE have equal effect on bleeding symptoms. Menstrual bleeding reduction six months after treatment is the main endpoint. Secondary endpoints include participants assessment of symptom relief, and volume reduction of fibroids measured by MRI. We will also investigate possible differences in postoperative course, symptom reduction, complication, and recurrence. Patients are controlled with regular intervals up to five years after treatment.

Detailed Description

Uterine fibroid embolization (UFE)has become an alternative to hysterectomy for women with symptoms of uterine fibroids.Follow up studies of this new method have reported relief of menstrual bleeding by 85-90 % of the patients six to twelve months after treatment.Other studies have suggested laparoscopic bilateral occlusion of uterine arteries as an equal effective alternative, but to our knowledge there is no randomized studies published.

Patients recruitment : Women with symptoms of uterine fibroids referred to the clinic,who express a desire to avoid hysterectomy.

Study hypothesis: Laparoscopic occlusion of uterine vessels and UFE have equal effect on bleeding symptoms.

Gynecological examination, ultrasonography and magnetic resonance imaging (MRI) are performed preoperatively and after 1,3 and 6 months. Clinical follow up is planned after 1,3,6,12,24,36 and 60 months.A validated bleeding chard, Pictorial Blood Assessment Chart(PBAC)is filled in by the participants during the last menstruation period before treatment and before each control. A standardized questionnaire to assess the bleeding amount,pressure symptoms, pain, adverse events, other complains and patients satisfaction is also used.

Study Timeline

• Study Start: 2000-12
• Status Verified: 2006-01
• Study First Submitted: 2006-01-12
• Study First Submitted QC: 2006-01-13
• Study First Posted: 2006-01-16
• Study Completion: 2010-04
• Last Update Submitted: 2011-07-03
• Last Update Posted: 2011-07-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Menorrhagia and/or bulk symptoms associated with uterine fibroids

Exclusion Criteria

• Malignancy
• Current or planned pregnancy
• Small submucous fibroids suitable for hysteroscopic resection
• Postmenopausal women
• Suspected or known adenomyosis
• Uterus size exceeding the umbilical level
• Contraindications against laparoscopic surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Reduction of menstrual bleeding six months after treatment measured by PBAC

Secondary Outcome Measures

Name	Time	Method
postoperative pain
recovering time
Patient assessment of symptom reduction including menorrhagia and bulk symptoms
complications
failures
recurrence
secondary interventions
Reduction in fibroids and uterus size measured by ultrasonography and MRI

Trial Locations

Locations (1)

Ullevål University Hospital; 🇳🇴 Oslo, Norway